Rett syndrome: How does Acadia’s trofinetide compare to ANAVEX2-73?
Now that Acadia’s trofinetide nabbed the first FDA approval for Rett syndrome, here’s a look at how Anavex’s Phase III candidate stacks up.

Now that Acadia’s trofinetide nabbed the first FDA approval for Rett syndrome, here’s a look at how Anavex’s Phase III candidate stacks up.
Organisations can use the platform to optimise their research efforts and minimise manual errors.
The global pharmaceutical industry experienced a 10% rise in new job postings related to social responsibility in Q3 2022 compared…
Atea Pharmaceuticals announces results of bemnifosbuvir for Covid-19
Clario launches comprehensive clinical trial solution
BWH’s investigators test Foralumab in pilot trial for Covid-19
Quantum medicine: how quantum computers could change drug development